5:47 PM
Jan 26, 2016
 |  BC Extra  |  Clinical News

Akashi halts DMD program

Akashi Therapeutics Inc. (Cambridge, Mass.) said it suspended dosing and enrollment of all clinical studies of HT-100 to treat Duchenne muscular dystrophy after a patient experienced undisclosed "serious, life-threatening health issues." The patient had been receiving 60 ug/kg of HT-100 daily, the study's highest dose, for about two weeks...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >